A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin

Stopped early · Phase 3

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted globally. The aim of the trial is to investigate the efficacy and safety of insulin detemir versus insulin Neutral Protamine Hagedorn (NPH) in combination with the maximum tolerated dose of metformin and diet/exercise on glycaemic control in children and adolescents with type 2 diabetes insufficiently controlled on the maximum tolerated dose of metformin with or without other oral antidiabetic drug(s) with or without basal insulin.

Key facts

Study ID

NCT02131272

Run by

Novo Nordisk A/S

People needed

42

Starts

2014-06-11

Expected to finish

2016-06-14

Last updated by the study team

2018-09-10

Who can join

Age: 10 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed consent from the subject or a legally acceptable representative (LAR) and child assent from the subject obtained before any trial-related activities.Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial
• Male or female, above or equal to 10 years and below or equal to 17 years at the time of signing informed consent/assent
• Diagnosis of type 2 diabetes mellitus at least 3 months prior to screening
• Treated with the maximum tolerated stable dose of metformin for at least 3 months prior to screening or have documented complete metformin intolerance
• HbA1c (glycosylated haemoglobin) above or equal to 7.0% and below or equal to 10.5% (above or equal to 53 mmol/mol and below or equal to 91 mmol/mol) at screening

You may not qualify if…

• Maturity onset diabetes of the young (MODY)
• Fasting C-peptide at screening below 0.6 ng/mL
• Impaired liver function defined as alanine aminotransferase (ALT) above or equal to 2.5 times upper normal limit
• Known proliferative retinopathy or maculopathy requiring acute treatment as judged by the investigator
• Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 3 months before the day of screening

Where it is running

• Novo Nordisk Investigational Site — Los Angeles, California, United States
• Novo Nordisk Investigational Site — Jacksonville, Florida, United States
• Novo Nordisk Investigational Site — Jacksonville, Florida, United States
• Novo Nordisk Investigational Site — Pembroke Pines, Florida, United States
• Novo Nordisk Investigational Site — Tallahassee, Florida, United States
• Novo Nordisk Investigational Site — Atlanta, Georgia, United States
• Novo Nordisk Investigational Site — Reisterstown, Maryland, United States
• Novo Nordisk Investigational Site — Silver Spring, Maryland, United States
• Novo Nordisk Investigational Site — Las Vegas, Nevada, United States
• Novo Nordisk Investigational Site — Buffalo, New York, United States
• Novo Nordisk Investigational Site — Cleveland, Ohio, United States
• Novo Nordisk Investigational Site — Toledo, Ohio, United States
• Novo Nordisk Investigational Site — Hershey, Pennsylvania, United States
• Novo Nordisk Investigational Site — Philadelphia, Pennsylvania, United States
• Novo Nordisk Investigational Site — Pittsburgh, Pennsylvania, United States
• Novo Nordisk Investigational Site — Providence, Rhode Island, United States
• Novo Nordisk Investigational Site — Columbia, South Carolina, United States
• Novo Nordisk Investigational Site — Memphis, Tennessee, United States
• Novo Nordisk Investigational Site — Amarillo, Texas, United States
• Novo Nordisk Investigational Site — Edinburg, Texas, United States
• Novo Nordisk Investigational Site — Norfolk, Virginia, United States
• Novo Nordisk Investigational Site — Milwaukee, Wisconsin, United States
• Novo Nordisk Investigational Site — CABA, Argentina
• Novo Nordisk Investigational Site — Aparecida de Goiânia, Goiás, Brazil
• Novo Nordisk Investigational Site — Tucson, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.